EQS-News

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million - Seite 2

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com.

* at current exchange rate CHF-EUR

For more information, please contact:

Newron
Stefan Weber – CEO
[phone]
[e-mail] 

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting
[phone]
[e-mail] 

Switzerland
Valentin Handschin, IRF
[phone]
[e-mail] 

Germany/Europe
Anne Hennecke / Caroline Bergmann, MC Services
[phone]
[e-mail] 

USA
Paul Sagan, LaVoieHealthScience
[phone], Ext. 112
[e-mail]

Important Notices
This document is not a prospectus within the meaning of the Swiss Financial Services Act and not a prospectus under any other applicable laws. Copies of this document may not be sent to, distributed in or sent from jurisdictions in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, any securities in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the applicable securities laws.